Autologous and allogenic HIV-1 proteins for the treatment of latent HIV-1 infection

A method of treating latent HIV infection in a subject, the method comprising:

• obtaining a biological sample from at least one allogenic HIV-1+ donor;
• diagnosing a chronic stage of infection of the at least one allogenic HIV-1+ donor;
• preparing from the biological sample at least one HIV-1 protein coding sequence;
• deriving at least one HIV-1 protein from the at least one HIV-1 protein coding sequence;
• administering to the subject a therapeutically effective amount of the at least one HIV-1 protein, and a pharmaceutically acceptable carrier;
• wherein the therapeutically effective amount of HIV-1 protein stimulates latent HIV-specific memory CD4+ T cells to induce latent HIV-1 replication resulting in HIV-specific memory-CD4+ T cell death in the subject;
• and
• administering a component of highly active antiretroviral therapy (HAART), wherein the component of HAART is selected from a nucleoside reverse transcriptase inhibitor, a non-nucleoside HIV reverse transcriptase inhibitor, and a protease inhibitor.